Greg Aronin is Chief Operating Officer of 32 Biosciences, where he leads operational execution as the company advances CS-0003, its first-in-class Mucosal-Immune Modulator, toward human clinical development. He brings more than 30 years of experience in corporate strategy, operations, external affairs, and organizational leadership across the biotechnology, pharmaceutical, and healthcare industries.

Previously, Greg served as Senior Vice President at Paragon Biosciences, where he contributed to corporate strategy, growth initiatives, brand development, and product reimbursement. He also led corporate affairs at Marathon Pharmaceuticals and held leadership roles across the pharmaceutical and medical-device businesses of Johnson & Johnson.

Greg earned a Master of Public Health from the University of Michigan and a Bachelor of Arts in International Relations from Michigan State University.

At 32 Biosciences, Greg focuses on scaling operations, coordinating cross-functional execution, optimizing resources, and preparing the organization for the transition from preclinical development to clinical-stage execution while aligning therapeutic development, functional biology, and strategic partnerships around the company’s upstream GI strategy.